What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study
By A. Hughes, Y. Ben-Shlomo, S. Daniel, Andrew Lees. Neurology, 2001
662 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/ca625b9308347ed2ec985a80eeabb470741b0605
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- I. Litvan
- Trevor W. Robbins
- Roger A. Barker
- Carol Brayne
- M. Stern
- T. Foltynie
- D. Burn
- Kailash Bhatia
Citations in the corpus
- The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. (2004, methodology): “…on the choice of inclusion criteria, as demonstrated in the Olmstead county study (Bower et al., 2000), and we have therefore adopted the UK Brain Bank criteria (Hughes et al., 1992a, b) as this is regarded by many as the most reliable way of making the clinical diagnosis of Parkinson's disease.”
- Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. (2002, result): “In the present study, the strict inclusion criteria maximized the likelihood that the subjects had idiopathic PD.46 Consistent with our findings of a reduction in the functional decline in PD are the results of a trial in which patients with early Huntington disease received coenzyme Q10 (600 mg/d),”
- SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders (2003, background): “The following items were identified and given weight (reported in brackets): poor (less than 50% subjective or objective) initial response to levodopa [2], presence of one or more features of autonomic failure [2], speech or bulbar problems present [3], absence of dementia [2], absence of toxic conf”
- Progressive Supranuclear Palsy (2001, background): “Because the diagnosis of PSP is not possible in all patients,[3] studies based on clinical diagnosis do not convey the same picture and there are no large clinical trials utilising one age group.”